Total
0
Shares
Pacific Knowledge Systems (ASX:PKS) - CEO, Ron van der Pluijm
CEO, Ron van der Pluijm
Sourced: Hot Copper
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Healthcare tech company, Pacific Knowledge Systems (PKS) has signed two renewal agreements for its clinical support solution, Rippledown
  • The renewal agreements are with two long-standing clients- Australian Clinical Laboratories and Healthscope New Zealand
  • RippleDown provides healthcare experts with real-time clinical analysis, interpretations and treatment recommendations
  • PKS is up 18.2 per cent on the market and is trading for 13¢ apiece

Healthcare tech company, Pacific Knowledge Systems (PKS) has signed two renewal agreements for its clinical decision support solution, Rippledown.

The renewal agreements are with Australian Clinical Laboratories and Healthscope New Zealand.

PKS develops and commercialises subscription-based clinical decision support (CDS) systems that automate the human decision-making process in healthcare organisations.

Rippledown

RippleDown helps provide healthcare experts, mainly pathologists or clinicians, real-time clinical analysis, interpretations and treatment recommendations.

By analysing the patient’s available information, RippleDown is able to provide interpretations and recommendations for that patient.

Australian Clinical Laboratories

PKS has signed a 3-year extension with Australian Clinical Laboratories (ACL) for Rippledown. ACL is Australia’s third largest private pathology provider and has been a customer of PKS since 2002.

PKS’ CEO Ron van der Pluijm is pleased to continue the relationship with its longstanding customer.

“We are looking forward to continuing to assist in delivering better patient outcomes and efficiencies utilising our RippleDown solution,” he said.

Healthscope NZ

The company has also signed a renewal agreement with another longterm customer, Healthscope NZ.

Healthscope NZ has been a customer of PKS since 2009.

“PKS is pleased to continue the close working relationship with Healthscope NZ. We are looking forward to continuing to assist in delivering better patient outcomes and efficiencies utilising our RippleDown solution,” Ron added.

PKS is up 18.2 per cent on the market and is trading for 13¢ apiece at 2:48 pm AEST.

PKS by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.